Audentes Therapeutics, Inc. (NASDAQ:BOLD) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday.

According to Zacks, “Audentes Therapeutics, Inc. is a biotechnology company which focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases. The company’s product pipeline consists of AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia and AT982 for the treatment of pompe disease, which are in pre-clinical trial stage. Audentes Therapeutics, Inc. is based in San Francisco, California. “

Other research analysts have also recently issued reports about the stock. Bank of America Corporation reissued a “buy” rating and set a $33.00 target price (up from $23.00) on shares of Audentes Therapeutics in a research report on Friday, September 22nd. ValuEngine cut shares of Audentes Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Finally, Evercore ISI assumed coverage on shares of Audentes Therapeutics in a research report on Wednesday, August 16th. They set an “outperform” rating and a $23.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $24.17.

Shares of Audentes Therapeutics (BOLD) traded up 3.67% during midday trading on Wednesday, hitting $27.67. 237,260 shares of the company’s stock were exchanged. Audentes Therapeutics has a 1-year low of $13.13 and a 1-year high of $33.43. The stock has a market cap of $768.78 million, a PE ratio of 6.90 and a beta of -0.04. The stock’s 50 day moving average is $26.73 and its 200-day moving average is $26.73.

Audentes Therapeutics (NASDAQ:BOLD) last posted its earnings results on Thursday, August 10th. The biotechnology company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.10). Analysts predict that Audentes Therapeutics will post ($3.50) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Zacks Investment Research Downgrades Audentes Therapeutics, Inc. (BOLD) to Sell” was reported by American Banking News and is the property of of American Banking News. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/10/11/zacks-investment-research-downgrades-audentes-therapeutics-inc-bold-to-sell.html.

In other Audentes Therapeutics news, CEO Matthew R. Patterson sold 15,000 shares of the business’s stock in a transaction on Thursday, July 13th. The shares were sold at an average price of $20.00, for a total transaction of $300,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Suyash Prasad sold 8,000 shares of the business’s stock in a transaction on Friday, September 1st. The shares were sold at an average price of $21.44, for a total transaction of $171,520.00. Following the sale, the vice president now owns 8,000 shares of the company’s stock, valued at approximately $171,520. The disclosure for this sale can be found here. Insiders sold 781,500 shares of company stock worth $21,743,730 over the last ninety days. 47.30% of the stock is currently owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the business. Wells Fargo & Company MN increased its stake in Audentes Therapeutics by 278.5% during the first quarter. Wells Fargo & Company MN now owns 7,747 shares of the biotechnology company’s stock valued at $132,000 after purchasing an additional 5,700 shares during the last quarter. Nationwide Fund Advisors increased its stake in Audentes Therapeutics by 288.9% during the second quarter. Nationwide Fund Advisors now owns 8,594 shares of the biotechnology company’s stock valued at $164,000 after purchasing an additional 6,384 shares during the last quarter. Citadel Advisors LLC bought a new stake in Audentes Therapeutics during the first quarter valued at $184,000. State of Wisconsin Investment Board bought a new stake in Audentes Therapeutics during the second quarter valued at $210,000. Finally, Rhumbline Advisers bought a new stake in Audentes Therapeutics during the second quarter valued at $252,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Get a free copy of the Zacks research report on Audentes Therapeutics (BOLD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Audentes Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.